Additionally, based on the spatial arrangement of CD8+PD-1+LAG3- T cells and the density of CD8+PD-1-LAG3-, CD68+STING+, and CD4+FoxP3-PD-L1+ cells, a multi-dimensional marker of tumor-infiltrating immune cells (TIICs) has been successfully developed to predict the response to immunotherapy [79]. This evidence concerns the gene PDCD1 and neoplasm.